The expression of constitutively active ABL1/2 in melanomas has been described to be sufficient to promote resistance to vemurafenib, dabrafenib, MEK inhibitors, and their combination by inducing reactivation of MEK/ERK/MYC signaling. Here, MAP2K7 is linked to melanoma.